Jan Astermark

39PUBLICATIONS
73CO-AUTHORS
Immunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)HaematologyMedical molecular engineering of nucleic acids and proteinsCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 23, 2026
Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A.

|Jun 24, 2026
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

|Jan 30, 2026
Nine areas with outstanding challenges for hemophilia B research.

Jan Astermark, Cédric Hermans, Peter J Lenting

|Sep 03, 2025
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study.

Jan Astermark, Susanna Ranta, Linda Myrin-Westesson

|Jun 19, 2025
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy.

Jan Astermark, Wolfgang Miesbach, Michiel Coppens

|Mar 18, 2025
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries-Comparisons to Matched Controls.

Katarina Steen Carlsson, Jan Astermark, Fariba Baghaei

Pageof 7

Frequent Collaborators

12 joint publications

Erik Berntorp

6 joint publications

Robert Klamroth

6 joint publications

Anna Olsson

6 joint publications

Victor Jiménez-Yuste